New Blood Pressure Breakthroughs Could Protect Your Heart—and Your Brain

Revolutionary research from 2025 shows that managing blood pressure more effectively can slash your risk of both heart disease and dementia, while a promising new medication is helping people with hard-to-treat hypertension. The American Heart Association's latest compilation of breakthrough studies reveals that nearly half of U.S. adults live with high blood pressure, making these discoveries potentially life-changing for millions.

How Does Better Blood Pressure Control Protect Your Brain?

A major study published in Nature Medicine involving nearly 34,000 adults in rural China found that aggressive blood pressure management significantly reduced dementia risk from any cause. Participants whose home villages received intensive blood pressure interventions achieved systolic pressures averaging 22.0 mm Hg lower and diastolic pressures 9.3 mm Hg lower than the usual care group over 48 months. Those in the intervention group were notably less likely to develop dementia.

"Sometimes it seems as though we're facing a losing battle as heart disease and stroke have continued to be the leading causes of death worldwide driven most recently in the U.S. by increases in risk factors and an aging population," said Dr. Mariell Jessup, chief medical and science officer of the American Heart Association.

What Makes This New Blood Pressure Drug Different?

Researchers have discovered that adding a medication called baxdrostat can help control hard-to-treat hypertension when other drugs fail. Published in The New England Journal of Medicine, the study of nearly 800 adults found impressive results:

• 2-mg Daily Dose: Systolic blood pressure dropped an average of 15.7 mm Hg after 12 weeks
• 1-mg Daily Dose: Blood pressure fell 14.5 mm Hg on average
• Placebo Group: Only saw a 5.8 mm Hg reduction

Baxdrostat works by blocking aldosterone synthase, the enzyme that produces aldosterone—a hormone released by the adrenal glands that helps regulate blood pressure by managing salt and potassium levels in the blood. While hyperkalemia (elevated potassium) occurred more often in the baxdrostat groups, the need to discontinue the medication because of elevated potassium was low.

Why Are These Findings So Important Now?

High blood pressure affects nearly half of all U.S. adults and is the most common and most modifiable risk factor for cardiovascular disease, according to the American Heart Association's 2025 guidelines. Cardiovascular disease claims nearly 950,000 lives in the U.S. annually and remains the leading cause of death worldwide.

The research also highlights five modifiable risk factors that account for about half the global burden of cardiovascular disease: abnormal body mass index (BMI), high systolic blood pressure, excess levels of non-high-density lipoprotein (non-HDL) cholesterol, smoking, and diabetes. These same factors contribute to cardiovascular-kidney-metabolic (CKM) syndrome, a newly defined condition affecting nearly 90% of adults.

A separate study of more than 2 million people worldwide found that men and women with none of these five risk factors at age 50 lived more than a decade longer than those with all the risk factors. Specifically, women without risk factors lived 14.5 years longer and had over 13 additional years free of cardiovascular disease, while men lived nearly 12 years longer with almost 11 additional disease-free years.

"Scientific research is a pillar of the American Heart Association and contributions from the scientific community like those we are highlighting this year are invaluable to our work to help everyone, everywhere live longer, healthier lives," said Dr. Stacey E. Rosen, volunteer president of the American Heart Association.